

Table 19.30
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2005-2011

Site		All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	94,857	68.6 (68.2 , 69.0)	89.0 (88.0 , 89.9)	74.7 (74.2 , 75.2)	58.2 (57.5 , 59.0)				
1 Hodgkin Lymphoma	8,183	85.1 (84.1 , 86.0)	97.1 (95.7 , 98.1)	88.5 (87.5 , 89.4)	52.9 (48.6 , 57.0)				
2 Non-Hodgkin lymphoma	84,404	67.5 (67.0 , 67.9)	87.0 (85.8 , 88.0)	73.1 (72.5 , 73.6)	58.9 (58.1 , 59.7)				
2(a) Non-Hodgkin lymphoma, B-cell	77,077	68.0 (67.5 , 68.4)	88.0 (86.6 , 89.2)	74.1 (73.5 , 74.6)	59.6 (58.8 , 60.4)				
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	4,066	68.3 (66.7 , 69.9)	87.5 (85.9 , 89.0)	36.9 (33.6 , 40.1)	17.2 (11.8 , 23.5)				
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	69,644	68.0 (67.5 , 68.5)	89.4 (86.7 , 91.5)	75.3 (74.8 , 75.9)	59.8 (59.0 , 60.6)				
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	18,227	76.6 (75.6 , 77.5)	- (- , -)	84.4 (83.2 , 85.5)	70.4 (68.9 , 71.9)				
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	15,668	80.0 (79.0 , 81.1)	- (- , -)	87.5 (86.2 , 88.6)	74.4 (72.7 , 75.9)				
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	68	52.3 (34.7 , 67.2)	- (- , -)	- (- , -)	44.9 (23.4 , 64.3)				
2(a) 2.1.3. Mantle-cell lymphoma	2,491	55.5 (52.7 , 58.1)	- (- , -)	67.1 (63.6 , 70.4)	44.4 (40.5 , 48.4)				
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,561	80.0 (76.4 , 83.1)	- (- , -)	87.4 (83.3 , 90.5)	75.2 (69.9 , 79.6)				
2(a) 2.2.1. Lymphoplasmacytic lymphoma	674	76.0 (70.4 , 80.7)	- (- , -)	83.0 (76.0 , 88.1)	71.3 (62.9 , 78.1)				
2(a) 2.2.2. Waldenstrom macroglobulinemia	887	83.0 (78.1 , 86.9)	- (- , -)	90.3 (84.8 , 93.9)	78.1 (70.9 , 83.7)				
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	17,982	61.2 (60.3 , 62.1)	88.2 (83.1 , 91.8)	68.1 (67.0 , 69.1)	52.1 (50.5 , 53.7)				
2(a) 2.3.1. DLBCL, NOS ^c	17,795	61.2 (60.3 , 62.1)	88.8 (83.7 , 92.3)	68.1 (66.9 , 69.1)	52.2 (50.6 , 53.8)				
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)				
2(a) 2.3.3. Primary effusion lymphoma	49	22.0 (9.5 , 37.8)	- (- , -)	21.8 (8.0 , 39.8)	- (- , -)				
2(a) 2.3.4. Mediastinal large B-cell lymphoma	116	79.1 (68.4 , 86.5)	- (- , -)	86.3 (75.3 , 92.6)	- (- , -)				
2(a) 2.4. Burkitt lymphoma/leukemia	1,604	60.7 (58.0 , 63.3)	88.8 (85.0 , 91.7)	56.5 (53.1 , 59.7)	30.7 (22.7 , 39.1)				
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,220	89.4 (87.5 , 91.1)	100.0 (- , -)	90.9 (88.9 , 92.6)	87.2 (84.1 , 89.8)				
2(a) 2.5.1. Splenic MZL	370	88.3 (80.9 , 93.0)	- (- , -)	83.7 (74.9 , 89.6)	91.1 (78.8 , 96.4)				
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,467	93.7 (91.1 , 95.6)	- (- , -)	94.4 (92.0 , 96.1)	92.3 (87.8 , 95.2)				
2(a) 2.5.3. Nodal MZL	1,383	81.7 (78.1 , 84.8)	- (- , -)	85.5 (81.2 , 88.9)	77.0 (71.4 , 81.7)				
2(a) 2.6. Follicular lymphoma	8,878	85.4 (84.2 , 86.5)	93.0 (73.6 , 98.3)	89.2 (88.0 , 90.3)	79.1 (76.6 , 81.4)				
2(a) 2.7. Hairy-cell leukemia	1,177	94.4 (91.4 , 96.4)	- (- , -)	97.2 (95.1 , 98.4)	85.8 (76.4 , 91.7)				
2(a) 2.8. Plasma cell neoplasms	15,973	47.5 (46.5 , 48.6)	- (- , -)	59.2 (57.7 , 60.7)	37.2 (35.7 , 38.8)				
2(a) 2.8.1. Plasmacytoma	1,131	69.9 (66.0 , 73.4)	- (- , -)	78.7 (74.4 , 82.4)	56.2 (48.8 , 62.9)				
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	14,842	45.8 (44.7 , 46.9)	- (- , -)	57.2 (55.6 , 58.8)	36.2 (34.6 , 37.7)				
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)				
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,367	67.6 (65.1 , 69.9)	91.4 (78.4 , 96.8)	74.0 (71.0 , 76.7)	62.0 (58.3 , 65.5)				

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2005-2011

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	6,229	63.1 (61.6 , 64.6)		84.3 (81.5 , 86.7)		65.0 (63.1 , 66.8)		49.0 (45.7 , 52.3)	
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	553	64.6 (60.1 , 68.7)		83.8 (78.8 , 87.8)		46.8 (39.6 , 53.6)		0.0 (- , -)	
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	5,644	63.0 (61.4 , 64.6)		84.5 (81.0 , 87.4)		66.3 (64.3 , 68.2)		50.0 (46.6 , 53.3)	
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,368	88.0 (84.7 , 90.6)		100.0 (- , -)		91.7 (88.6 , 94.1)		78.9 (70.4 , 85.2)	
2(b) 2.1.1. Mycosis fungoides	1,325	89.5 (86.2 , 92.1)		100.0 (- , -)		92.7 (89.5 , 94.9)		81.4 (72.5 , 87.7)	
2(b) 2.1.2. Sezary syndrome	43	37.1 (17.2 , 57.1)		- (- , -)		- (- , -)		35.2 (12.3 , 59.5)	
2(b) 2.2. Peripheral T-cell lymphoma	3,207	55.5 (53.3 , 57.6)		80.4 (73.3 , 85.8)		61.2 (58.5 , 63.7)		42.8 (39.0 , 46.6)	
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,121	37.1 (33.4 , 40.7)		61.5 (41.2 , 76.7)		42.7 (37.9 , 47.4)		27.5 (21.8 , 33.4)	
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	373	38.8 (32.7 , 44.8)		- (- , -)		51.1 (42.1 , 59.4)		26.7 (18.8 , 35.2)	
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	28	75.1 (34.8 , 92.5)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	715	55.8 (51.7 , 59.7)		88.2 (80.0 , 93.1)		56.6 (51.4 , 61.4)		33.6 (25.1 , 42.2)	
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	34	24.1 (9.8 , 41.8)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	30	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	615	82.7 (77.7 , 86.7)		- (- , -)		86.5 (80.9 , 90.5)		76.5 (66.0 , 84.1)	
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	291	90.9 (84.9 , 94.6)		- (- , -)		95.6 (89.7 , 98.2)		81.9 (65.3 , 91.1)	
2(b) 2.3. Adult T-cell leukemia/lymphoma	663	62.5 (58.0 , 66.7)		85.8 (81.3 , 89.3)		40.0 (32.4 , 47.5)		- (- , -)	
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	282	41.1 (34.4 , 47.6)		- (- , -)		40.3 (32.9 , 47.6)		34.4 (18.2 , 51.3)	
2(b) 2.5. T-cell large granular lymphocytic leukemia	51	60.7 (42.0 , 75.0)		- (- , -)		- (- , -)		47.0 (23.1 , 67.8)	
2(b) 2.6. Prolymphocytic leukemia, T-cell	73	14.6 (5.5 , 27.7)		- (- , -)		15.1 (4.5 , 31.5)		- (- , -)	
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	32	43.7 (25.7 , 60.4)		- (- , -)		- (- , -)		- (- , -)	
2(c) Non-Hodgkin lymphoma, unknown lineage	1,098	57.7 (54.3 , 60.9)		83.9 (79.1 , 87.6)		51.6 (46.4 , 56.7)		40.5 (34.1 , 46.9)	
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	503	63.3 (58.6 , 67.5)		84.1 (79.3 , 87.9)		31.4 (23.1 , 39.9)		25.6 (14.1 , 38.9)	
2(c) 2. Prolymphocytic leukemia, unknown lineage	29	44.6 (24.5 , 62.9)		- (- , -)		- (- , -)		- (- , -)	
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	566	53.1 (48.0 , 57.9)		- (- , -)		61.1 (54.5 , 67.0)		43.7 (36.0 , 51.2)	
2(*) 1. Total precursor lymphoma/leukemia ^d	5,122	67.5 (66.0 , 68.9)		86.9 (85.5 , 88.2)		38.1 (35.3 , 40.8)		17.9 (13.1 , 23.3)	
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	45	78.3 (57.7 , 89.7)		- (- , -)		75.5 (54.1 , 87.9)		- (- , -)	
4 Lymphoid neoplasm, NOS ^c	2,225	49.4 (46.7 , 52.0)		81.9 (63.9 , 91.4)		58.8 (55.2 , 62.3)		40.3 (36.3 , 44.3)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.